INSM vs. RVTY: Insmed vs. Revvity Stock Comparison

November 11, 2026

How do Insmed (INSM) and Revvity (RVTY) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Insmed (INSM) and Revvity (RVTY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but INSM is classified in Biotechnology while RVTY is classified in Life Sciences Tools & Services.

Company profile comparison for Insmed (INSM) and Revvity (RVTY)
Profile Item	INSM	RVTY
Name	Insmed Incorporated	Revvity Inc.
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Life Sciences Tools & Services
GICS Sub-Industry	Biotechnology	Life Sciences Tools & Services
Market Capitalization	25.10 billion USD	17.31 billion USD
Currency	USD	USD
Exchange	Nasdaq	NYSE
Listing Date	June 1, 2000	February 21, 1973
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

INSM

RVTY

GSPC

Insmed (INSM) vs. Revvity (RVTY), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Insmed (INSM) and Revvity (RVTY). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Insmed (INSM) and Revvity (RVTY). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Insmed (INSM) and Revvity (RVTY)
Metric	INSM	RVTY
Total Return (1Y)	-39.17%	76.75%
Total Return (3Y, Annualized)	70.17%	24.22%
Total Return (5Y, Annualized)	28.96%	-1.48%

Risk Profile

Drawdown History

INSM

RVTY

GSPC

Insmed (INSM) vs. Revvity (RVTY), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Insmed (INSM) and Revvity (RVTY). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Insmed (INSM) and Revvity (RVTY)
Metric	INSM	RVTY
Volatility (1Y, Annualized)	63.09%	40.22%
Beta (5Y)	0.80	1.07
Max Drawdown (5Y)	-56.54%	-59.01%
Avg. Volume (3M)	2.76M	1.89M

Risk-Adjusted Performance

Risk-Return Positioning

INSM and RVTY are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Insmed (INSM) and Revvity (RVTY)
Metric	INSM	RVTY
Sharpe Ratio (1Y)	-0.69	1.80
Sortino Ratio (1Y)	-1.04	2.90

Profitability

ROE (TTM)

Insmed (INSM) reports a negative ROE of -72.45%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Revvity (RVTY) reports 3.45%, ranking against industry peers normally.

INSM

Pharmaceuticals, Biotechnology & Life Sciences industry group

-72.45%

Max: 109.18%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
INSM: -72.45%
Min: -167.77%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.45%

Max: 109.18%
Q3: 6.23%
RVTY: 3.45%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Insmed (INSM) vs. Revvity (RVTY): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Insmed (INSM) reports a negative net margin of -39.85%, usually indicating a net loss over the period. Meanwhile Revvity (RVTY) reports 8.61%, ranking against industry peers normally.

INSM

Pharmaceuticals, Biotechnology & Life Sciences industry group

-39.85%

Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%
INSM: -39.85%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.61%

Max: 18.05%
RVTY: 8.61%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Insmed (INSM) vs. Revvity (RVTY): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Insmed (INSM) reports a negative operating margin of -15.60%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Revvity (RVTY) reports 17.06%, ranking against industry peers normally.

INSM

Pharmaceuticals, Biotechnology & Life Sciences industry group

-15.60%

Max: 83.12%
Q3: 14.77%
Median: 0.00%
INSM: -15.60%
Q1: -78.82%
Min: -207.40%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

17.06%

Max: 83.12%
RVTY: 17.06%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Insmed (INSM) vs. Revvity (RVTY): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Insmed (INSM) and Revvity (RVTY)
Metric	INSM	RVTY
ROE (TTM)	-72.45%	3.45%
ROA (TTM)	-17.25%	2.54%
Net Margin (TTM)	-39.85%	8.61%
Operating Margin (TTM)	-15.60%	17.06%
Gross Margin (TTM)	84.40%	55.91%

Growth

Revenue Growth

Insmed (INSM) at 66.73% sits in the top revenue growth quartile, while Revvity (RVTY) at 3.67% is closer to the peer norm — faster top-line expansion for INSM.

Insmed (INSM) vs. Revvity (RVTY): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Revvity (RVTY) reports EPS growth of -5.91%, ranked against its industry; Insmed (INSM) has no EPS growth figure this period.

Insmed (INSM) vs. Revvity (RVTY): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Insmed (INSM) and Revvity (RVTY)
Metric	INSM	RVTY
Revenue Growth (YoY)	66.73%	3.67%
Revenue Growth (3Y CAGR)	35.20%	-4.82%
EPS Growth (YoY)	--	-5.91%
EPS Growth (3Y CAGR)	--	-23.26%

Financial Strength

Current Ratio (MRQ)

Both Insmed (INSM) at 2.86 and Revvity (RVTY) at 2.65 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

INSM

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.86

Max: 25.13
Q3: 12.13
Median: 5.52
INSM: 2.86
Q1: 2.47
Min: 0.10

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.65

Max: 25.13
Q3: 12.13
Median: 5.52
RVTY: 2.65
Q1: 2.47
Min: 0.10

Insmed (INSM) vs. Revvity (RVTY): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Revvity (RVTY) at 0.38 carries an industry-typical debt-to-equity mix, while Insmed (INSM) at 1.01 uses more debt funding than most peers.

INSM

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.01

Max: 1.42
INSM: 1.01
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.38

Max: 1.42
Q3: 0.65
RVTY: 0.38
Median: 0.15
Q1: 0.02
Min: 0.00

Insmed (INSM) vs. Revvity (RVTY): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Insmed (INSM) and Revvity (RVTY)
Metric	INSM	RVTY
Current Ratio (MRQ)	2.86	2.65
Debt / Equity (MRQ)	1.01	0.38
Net Debt / EBITDA	--	2.43

Dividends

Dividend Yield (TTM)

Insmed (INSM) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Revvity (RVTY) reports a yield of 0.19%, ranking against industry peers normally.

INSM

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

INSM: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.19%

RVTY: 0.19%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Insmed (INSM) vs. Revvity (RVTY): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Insmed (INSM) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Revvity (RVTY) reports a payout of 13.40%, ranking against industry peers normally.

INSM

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

INSM: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.40%

RVTY: 13.40%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Insmed (INSM) vs. Revvity (RVTY): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Insmed (INSM) and Revvity (RVTY)
Metric	INSM	RVTY
Dividend Yield (TTM)	0.00%	0.19%
Dividend Payout Ratio (TTM)	0.00%	13.40%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Revvity (RVTY) trades at 68.94 times trailing earnings, ranked against its peers, while Insmed (INSM) has no P/E ratio this period.

INSM

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07
INSM: --

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

68.94

Max: 85.34
RVTY: 68.94
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

Insmed (INSM) vs. Revvity (RVTY): INSM does not report P/E ratio, so it has no value marker; RVTY is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

On P/S ratio, both Insmed (INSM) at 16.52 and Revvity (RVTY) at 5.88 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

INSM

Pharmaceuticals, Biotechnology & Life Sciences industry group

16.52

Max: 58.18
Q3: 25.77
INSM: 16.52
Median: 7.30
Q1: 3.01
Min: 0.01

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.88

Max: 58.18
Q3: 25.77
Median: 7.30
RVTY: 5.88
Q1: 3.01
Min: 0.01

Insmed (INSM) vs. Revvity (RVTY): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Revvity (RVTY) at 2.39 sits near its industry’s typical P/B ratio, while Insmed (INSM) at 34.55 prices above its benchmark range — INSM looks rich relative to book.

INSM

Pharmaceuticals, Biotechnology & Life Sciences industry group

34.55

INSM: 34.55
Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.39

Max: 13.53
Q3: 6.54
Median: 3.25
RVTY: 2.39
Q1: 1.69
Min: -5.59

Insmed (INSM) vs. Revvity (RVTY): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Insmed (INSM) and Revvity (RVTY)
Metric	INSM	RVTY
P/E Ratio (TTM)	--	68.94
P/S Ratio (TTM)	16.52	5.88
P/B Ratio (MRQ)	34.55	2.39
Free Cash Flow Yield (TTM)	-1.82%	3.62%